Stelis BioSource™ is the Contract Development and Manufacturing Services arm of Stelis Biopharma. We are a one-stop shop with comprehensive capabilities from Cell line and Process Development through to scale up, cGMP manufacturing and fill/finish of proteins and peptides.
We offer services at every stage of the development life cycle from Pre-Clinical and Clinical Development to Commercial Supply. At Stelis BioSource™, we assure customers of CDMO/CMO services, our deep commitment to Quality, Service and Compliance. We have made significant investments in setting up world-class infrastructure for R&D, Scale Up and cGMP commercial manufacturing with dedicated capacities for contract manufacturing.
Importantly, we have built skilled teams in Manufacturing, Quality, Technology transfer with deep experience in handling biopharma operations in leading companies. Our strategic location in Bangalore, India leverages the advantages of an emerging technological hub for R&D and next generation manufacturing. India is among the top 12 biotech destinations in the world and 3rd in Asia-Pacific after Japan and South Korea. India has the 2nd highest number of FDA approved facilities after USA and we are close to growth markets in ASEAN and MENA region.
The principal shareholders of Stelis are:
- Strides Pharma Bangalore, India (www.strides.com)
- Tenshi Life Sciences Pvt. Ltd Bangalore, India
- GMS Holdings Amman, Jordan (www.gmsholdings.com)